Skip to main content
. 2020 Sep 11;42(6):998–1004. doi: 10.1038/s41401-020-00513-3

Fig. 3. SAF-189s shows potent antitumor efficacy against ROS1 wild-type- and G2032R mutant-driven tumors.

Fig. 3

Nude mice bearing BaF3/CD74–ROS1 (a) or BaF3/CD74–ROS1G2032R (b) subcutaneous xenografts were administered vehicle or the compounds once daily for 14 days. The values shown in a and b represent the mean ± SEM. c, d Tumor samples were collected at the end of treatment, and intratumoral Ki67 expression was assessed by immunohistochemical (IHC) analysis. BaF3/CD74–ROS1 (c) or BaF3/CD74–ROS1G2032R (d). Nude mice bearing BaF3/CD74–ROS1 (e) or BaF3/CD74–ROS1G2032R (f) subcutaneous xenografts were administered vehicle or compounds once daily for 14 days. Body weights were measured twice a week and are shown as the mean ± SEM. The values shown in a and b represent the mean ±  SEM. ***P < 0.001; by one-way ANOVA.